{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "bad32605",
   "metadata": {},
   "source": [
    "# RAG Pipeline Exercise\n",
    "\n",
    "In this exercise you will build and **compare two simple Retrieval-Augmented Generation (RAG) pipelines**.\n",
    "\n",
    "You will work with a small collection of PDF documents (e.g. medical guidelines) and:\n",
    "\n",
    "1. Load and chunk the PDF documents.\n",
    "2. Create a vector index using **embedding model A** (local `BAAI/bge-m3`).\n",
    "3. Create a second index using **embedding model B** (e.g. OpenAI or Gemini embeddings).\n",
    "4. Implement a simple **retriever** and an **answering function** that calls an LLM with retrieved context.\n",
    "5. Automatically **generate questions** from the documents and use them to **compare two RAG configurations**.\n",
    "\n",
    "Cells marked with `# TODO` are **for students to implement**.\n",
    "Everything else is provided scaffolding."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4ddf82e6",
   "metadata": {},
   "source": [
    "## 0. Setup & Imports"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "be93ec53",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/usr/local/python/3.12.1/lib/python3.12/site-packages/tqdm/auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    }
   ],
   "source": [
    "# TODO (easy): skim the imports and make sure you understand what each library is used for.\n",
    "\n",
    "from dotenv import load_dotenv\n",
    "import os\n",
    "import glob\n",
    "from PyPDF2 import PdfReader\n",
    "from langchain_text_splitters import RecursiveCharacterTextSplitter\n",
    "import faiss\n",
    "from sentence_transformers import SentenceTransformer\n",
    "import pickle\n",
    "import random\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "\n",
    "# LLM / API clients (we will mainly use OpenAI here; Gemini can be added as a bonus)\n",
    "from openai import OpenAI"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "68f16980",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load API keys from .env (you need to create this file once and add your keys)\n",
    "load_dotenv()\n",
    "\n",
    "deepinfra_key = os.getenv(\"DEEPINFRA_API_KEY\")\n",
    "openai_api_key = os.getenv(\"OPENAI_API_KEY\")\n",
    "google_api_key = os.getenv(\"GOOGLE_API_KEY\")\n",
    "anthropic_api_key = os.getenv(\"ANTHROPIC_API_KEY\")\n",
    "\n",
    "# For this exercise we mainly use OpenAI for both embeddings (RAG B) and chat completions.\n",
    "assert openai_api_key is not None, \"Please set OPENAI_API_KEY in your .env file.\"\n",
    "openai_client = OpenAI(api_key=openai_api_key)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "23ebcf52",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Make pandas show the full table and full cell content\n",
    "pd.set_option(\"display.max_rows\", None)       # show all rows\n",
    "pd.set_option(\"display.max_columns\", None)    # show all columns\n",
    "pd.set_option(\"display.max_colwidth\", None)   # don't truncate cell text"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "fba2719d",
   "metadata": {},
   "source": [
    "## 1. Load PDF documents\n",
    "\n",
    "We assume there is a `data/` folder containing one or more PDF files.\n",
    "\n",
    "**Task:** implement `load_pdfs(glob_path)` so that it:\n",
    "- Iterates over all PDF files matching `glob_path`\n",
    "- Reads them with `PdfReader`\n",
    "- Concatenates the text of all pages into **one long string**."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "d8abcb21",
   "metadata": {},
   "outputs": [],
   "source": [
    "def load_pdfs(glob_path: str = \"data/*.pdf\") -> str:\n",
    "    \"\"\"Load all PDFs matching the pattern and return their combined text.\n",
    "\n",
    "    TODO:\n",
    "    - Use `glob.glob(glob_path)` to iterate over file paths\n",
    "    - For each file, open it in binary mode and create a `PdfReader`\n",
    "    - Loop over `reader.pages` and extract text with the extract_text() function\n",
    "    - Concatenate everything into a single string `text`\n",
    "    - Be robust: skip pages where `extract_text()` returns None\n",
    "    \"\"\"\n",
    "    # YOUR CODE HERE\n",
    "    text = \"\"\n",
    "    for pdf_path in glob.glob(glob_path):\n",
    "        with open(pdf_path, \"rb\") as f:\n",
    "            reader = PdfReader(f)\n",
    "            for page in reader.pages:\n",
    "                page_text = page.extract_text()\n",
    "                if page_text:\n",
    "                    text += \" \" + page_text\n",
    "    return text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "416c3ad0",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of characters: 279338\n",
      "Preview:  High and normal protein diets improve body composition and \n",
      "glucose control in adults with type 2 diabetes: A randomized \n",
      "trial\n",
      "Julianne G. Clina1, R. Drew Sayer1,3, Zhaoxing Pan2, Caroline W. Cohen3, Michael T. \n",
      "McDermott4, Victoria A. Catenacci4, Holly R. Wyatt1,5, James O. Hill1\n",
      "1Department of Nutrition Sciences, University of Alabama at Birmingham\n",
      "2Department of Pediatrics, University of Colorado Anschutz Medical Campus\n",
      "3Department of Family and Community Medicine, University of Alabama at \n"
     ]
    }
   ],
   "source": [
    "# Run once and inspect\n",
    "raw_text = load_pdfs(\"data/*.pdf\")\n",
    "print(\"Number of characters:\", len(raw_text))\n",
    "print(\"Preview:\", raw_text[:500])"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "5c0c5a14",
   "metadata": {},
   "source": [
    "## 2. Chunk the text\n",
    "\n",
    "We will split the long text into overlapping chunks.\n",
    "\n",
    "Later you can **experiment** with different `chunk_size` and `chunk_overlap` to see how it affects retrieval.\n",
    "\n",
    "**Task:** start with the given parameters, run once, then try at least one alternative configuration and note the effects."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "a4e3f802",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "RAG A: 157 chunks produced, first chunk length = 1954\n",
      "RAG B: 315 chunks produced, first chunk length = 981\n"
     ]
    }
   ],
   "source": [
    "# Base configuration (RAG A)\n",
    "chunk_size_a = 2000\n",
    "chunk_overlap_a = 200\n",
    "\n",
    "splitter_a = RecursiveCharacterTextSplitter(\n",
    "    chunk_size=chunk_size_a,\n",
    "    chunk_overlap=chunk_overlap_a\n",
    ")\n",
    "\n",
    "chunks_a = splitter_a.split_text(raw_text)\n",
    "print(f\"RAG A: {len(chunks_a)} chunks produced, first chunk length = {len(chunks_a[0])}\")\n",
    "\n",
    "# TODO (mini-experiment): change chunk_size / chunk_overlap for RAG B and compare\n",
    "chunk_size_b = 1000   # e.g. smaller chunks\n",
    "chunk_overlap_b = 100\n",
    "\n",
    "splitter_b = RecursiveCharacterTextSplitter(\n",
    "    chunk_size=chunk_size_b,\n",
    "    chunk_overlap=chunk_overlap_b\n",
    ")\n",
    "\n",
    "chunks_b = splitter_b.split_text(raw_text)\n",
    "print(f\"RAG B: {len(chunks_b)} chunks produced, first chunk length = {len(chunks_b[0])}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ec3511f4",
   "metadata": {},
   "source": [
    "## 3. Create embeddings and a FAISS index\n",
    "\n",
    "We start with **Embedding model A: `BAAI/bge-small-en`** using `sentence-transformers`.\n",
    "\n",
    "Then, as an optional extension, you can build **Embedding model B** using OpenAI or Gemini and compare.\n",
    "\n",
    "To keep the exercise manageable, the base version only **requires** BGE."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "b519161f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Embedding dimensionality (A): 384\n",
      "FAISS index (A) size: 157\n"
     ]
    }
   ],
   "source": [
    "# Embedding model A (local)\n",
    "model_name_a = \"BAAI/bge-small-en\"\n",
    "embedder_a = SentenceTransformer(model_name_a)\n",
    "\n",
    "# Compute embeddings for all chunks of configuration A\n",
    "embeddings_a = embedder_a.encode(chunks_a, convert_to_numpy=True)\n",
    "\n",
    "dimensions_a = embeddings_a.shape[1]\n",
    "print(\"Embedding dimensionality (A):\", dimensions_a)\n",
    "\n",
    "index_a = faiss.IndexFlatL2(dimensions_a)\n",
    "index_a.add(embeddings_a)\n",
    "print(\"FAISS index (A) size:\", index_a.ntotal)\n",
    "\n",
    "# Persist index/chunks if you like (optional)\n",
    "os.makedirs(\"faiss\", exist_ok=True)\n",
    "faiss.write_index(index_a, \"faiss/faiss_index_a.index\")\n",
    "with open(\"faiss/chunks_a.pkl\", \"wb\") as f:\n",
    "    pickle.dump(chunks_a, f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "77271916",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "FAISS index (B) size: 315\n"
     ]
    }
   ],
   "source": [
    "# Embedding model B using OpenAI embeddings.\n",
    "\n",
    "# TODO:\n",
    "# - Use `openai_client.embeddings.create(...)` to compute embeddings for `chunks_b`\n",
    "# - Create a second FAISS index `index_b`\n",
    "# - Make sure to check the dimensionality from the first embedding vector\n",
    "\n",
    "# Example sketch (not complete, adapt & run if you have API access):\n",
    "# Initialize OpenAI client\n",
    "openai_client = OpenAI(api_key=openai_api_key)\n",
    "response = openai_client.embeddings.create(\n",
    "     model=\"text-embedding-3-small\",\n",
    "    input=chunks_b\n",
    ")\n",
    "embeddings_b = np.array([item.embedding for item in response.data])\n",
    "dim_b = embeddings_b.shape[1]\n",
    "index_b = faiss.IndexFlatL2(dim_b)\n",
    "index_b.add(embeddings_b)\n",
    "print(\"FAISS index (B) size:\", index_b.ntotal)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "0339224e",
   "metadata": {},
   "source": [
    "## 4. Implement a simple retriever\n",
    "\n",
    "We now implement a generic retrieval function that:\n",
    "1. Embeds the query.\n",
    "2. Searches the FAISS index.\n",
    "3. Returns the corresponding text chunks.\n",
    "\n",
    "We implement it for configuration A. If you built configuration B, you can reuse the same function."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "aa6fbf82",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of retrieved chunks: 3\n",
      "Preview of first chunk: likely to be normal). [NICE 2017] \n",
      "1.2 O bjective tests f or diagnosing asthma in adul ts, \n",
      "young pe ople and childr en ag ed 5 to 16 wi th a \n",
      "histor y sug gestive of asthma \n",
      "Adults \n",
      "See also algorit hm A f or a summar y of objectiv e tests for diagnosing ast hma in adult s and \n",
      "young people (aged o ver 16 y ears) wit h a hist ory suggesting ast hma. Asthma: diagnosis, monit oring and chr onic ast\n"
     ]
    }
   ],
   "source": [
    "def retrieve_texts(query: str, k: int, index, chunks, embedder) -> list:\n",
    "    \"\"\"Return the top-k most similar chunks for a query.\n",
    "\n",
    "    TODO (students):\n",
    "    - Encode the query with `embedder.encode(...)`\n",
    "    - Call `index.search(query_embedding, k)`\n",
    "    - Use the returned indices to select the chunks\n",
    "    - Return a list of strings (chunks)\n",
    "    \"\"\"\n",
    "    # YOUR CODE HERE\n",
    "    query_emb = embedder.encode([query], convert_to_numpy=True)\n",
    "    distances, indices = index.search(query_emb, k)\n",
    "    retrieved = [chunks[i] for i in indices[0]]\n",
    "    return retrieved\n",
    "\n",
    "# Quick sanity check\n",
    "test_query = \"What is the most important factor in diagnosing asthma?\"\n",
    "retrieved_text = retrieve_texts(test_query, k=3, index=index_a, chunks=chunks_a, embedder=embedder_a)\n",
    "print(\"Number of retrieved chunks:\", len(retrieved_text))\n",
    "print(\"Preview of first chunk:\", retrieved_text[0][:400])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "84287470",
   "metadata": {},
   "outputs": [],
   "source": [
    "def openai_embed_query(query: str) -> np.ndarray:\n",
    "    \"\"\"\n",
    "    Compute an OpenAI embedding for a single query string and\n",
    "    return it as a NumPy array of shape (1, dim).\n",
    "    \"\"\"\n",
    "    resp = openai_client.embeddings.create(\n",
    "        model=\"text-embedding-3-small\",\n",
    "        input=[query]  # list with one string\n",
    "    )\n",
    "    vec = np.array(resp.data[0].embedding, dtype=\"float32\")\n",
    "    return vec.reshape(1, -1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "68ab8b40",
   "metadata": {},
   "outputs": [],
   "source": [
    "def retrieve_texts_b(query: str, k: int, index, chunks) -> list:\n",
    "    \"\"\"\n",
    "    Retrieve top-k chunks using OpenAI embeddings for the query.\n",
    "    \"\"\"\n",
    "    query_emb = openai_embed_query(query)  # shape (1, dim)\n",
    "    distances, indices = index.search(query_emb, k)\n",
    "    retrieved = [chunks[i] for i in indices[0]]\n",
    "    return retrieved"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f646fdc6",
   "metadata": {},
   "source": [
    "## 5. Implement `answer_query` using an LLM\n",
    "\n",
    "Now we build the actual RAG call:\n",
    "\n",
    "1. Use `retrieve_texts` to get top-`k` chunks.\n",
    "2. Concatenate them into a context string.\n",
    "3. Build a prompt that:\n",
    "   - shows the context\n",
    "   - asks the model to answer the user question based **only** on this context.\n",
    "4. Call the OpenAI chat completion API.\n",
    "\n",
    "This is the **core RAG function**."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "0d94610c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "RAG answer: The most important factor in diagnosing asthma, according to the context, is measuring the blood eosinophil count or fractional exhaled nitric oxide (FeNO) level in adults with a history suggestive of asthma. Asthma can be diagnosed if the eosinophil count is above the laboratory reference range or the FeNO level is 50 ppb or more.\n"
     ]
    }
   ],
   "source": [
    "def answer_query_a(query: str, k: int, index, chunks, embedder, client: OpenAI) -> str:\n",
    "    \"\"\"RAG-style answer: retrieve context and ask an LLM.\n",
    "\n",
    "    TODO (students):\n",
    "    - Use `retrieve_texts` to get `k` relevant chunks.\n",
    "    - Join them into a single context string.\n",
    "    - Build a chat prompt that instructs the model to answer *only* using the context.\n",
    "    - Call `client.chat.completions.create(...)` with model `\"gpt-4o-mini\"` (or similar).\n",
    "    - Return the model's answer text.\n",
    "    \"\"\"\n",
    "    retrieved_chunks = retrieve_texts(query, k, index, chunks, embedder)\n",
    "    context = \"\\n\\n---\\n\\n\".join(retrieved_chunks)\n",
    "\n",
    "    system_prompt = (\n",
    "        \"You are a helpful assistant answering questions based ONLY on the provided context. \"\n",
    "        \"If the answer is not in the context, say that you do not know.\"\n",
    "    )\n",
    "\n",
    "    messages = [\n",
    "        {\"role\": \"system\", \"content\": system_prompt},\n",
    "        {\"role\": \"user\", \"content\": f\"Context:\\n{context}\\n\\nQuestion: {query}\"}\n",
    "    ]\n",
    "\n",
    "    completion = client.chat.completions.create(\n",
    "        model=\"gpt-4o-mini\",\n",
    "        messages=messages\n",
    "    )\n",
    "\n",
    "    return completion.choices[0].message.content.strip()\n",
    "\n",
    "# Quick manual test\n",
    "answer = answer_query_a(test_query, k=3, index=index_a, chunks=chunks_a, embedder=embedder_a, client=openai_client)\n",
    "print(\"RAG answer:\", answer)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4b13aade",
   "metadata": {},
   "source": [
    "### Answer Function with the other embedding type"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "5994c414",
   "metadata": {},
   "outputs": [],
   "source": [
    "def answer_query_b(query: str, k: int, index, chunks, client: OpenAI) -> str:\n",
    "    \"\"\"\n",
    "    RAG-style answer for configuration B (OpenAI embeddings + chunking B).\n",
    "    \"\"\"\n",
    "    retrieved_chunks = retrieve_texts_b(query, k, index, chunks)\n",
    "    context = \"\\n\\n---\\n\\n\".join(retrieved_chunks)\n",
    "\n",
    "    system_prompt = (\n",
    "        \"You are a helpful assistant answering questions based ONLY on the provided context. \"\n",
    "        \"If the answer is not in the context, say that you do not know.\"\n",
    "    )\n",
    "\n",
    "    messages = [\n",
    "        {\"role\": \"system\", \"content\": system_prompt},\n",
    "        {\"role\": \"user\", \"content\": f\"Context:\\n{context}\\n\\nQuestion: {query}\"},\n",
    "    ]\n",
    "\n",
    "    completion = client.chat.completions.create(\n",
    "        model=\"gpt-4o-mini\",\n",
    "        messages=messages,\n",
    "    )\n",
    "\n",
    "    return completion.choices[0].message.content.strip()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7a86a92e",
   "metadata": {},
   "source": [
    "## 6. Generate questions from random chunks (automatic evaluation set)\n",
    "\n",
    "To compare two RAG configurations, we need **questions**.\n",
    "\n",
    "We will:\n",
    "- randomly sample a few chunks from the corpus,\n",
    "- ask an LLM to generate a **good question** whose answer is contained in the chunk.\n",
    "\n",
    "Then we can use these question–chunk pairs as a small evaluation set.\n",
    "\n",
    "We provide most of the implementation. Your job is mainly to:\n",
    "- inspect the code,\n",
    "- understand the prompt,\n",
    "- maybe tweak the number of chunks or retries."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "eb899fb6",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Q1: What are the key considerations and potential impacts of the BTS/NICE/SIGN recommendations for the initial treatment and management of asthma in children and adults, particularly regarding the efficacy of combining ICS with as-needed SABA versus other strategies?\n",
      "  From chunk preview: (ICS) r egimens (using SABA [shor t-acting beta 2 agonist] as a r eliever) compar ed wit h 'as-\n",
      "needed' strat egies (f o...\n",
      "\n",
      "Q2: What are the key components of care and guidelines that health professionals in England and Scotland should consider when diagnosing and managing patients with suspected asthma and how do these relate to principles of shared decision-making and patient experience?\n",
      "  From chunk preview: • Shar ed decision making \n",
      "• Medicines adher ence \n",
      "• Multimorbidity . \n",
      "In addition, healt h professionals in England sho...\n",
      "\n",
      "Q3: How do the changes in glucose, HbA1c, and insulin levels over 52 weeks differ between high protein (HP) and normal protein (NP) diet groups in relation to type 2 diabetes management?\n",
      "  From chunk preview: Fat Mass, % 46.2 ± 6.2 46.6 ± 5.9\n",
      " Fat-Free Mass, % 52.9 ± 6.1 52.4 ± 5.8\n",
      "Biomarkers  (M±SD)\n",
      " HOMA-IR 7.6 ± 7.0 5.9 ± 3....\n",
      "\n",
      "Q4: What methodological approaches were employed in the study design to ensure accurate blood pressure measurements and statistical analysis of weight loss between the high-protein (HP) and normal-protein (NP) diet groups?\n",
      "  From chunk preview: Japan). Blood pressure was measured after the participant rested quietly in a seated position \n",
      "for ≥5 min with participa...\n",
      "\n",
      "Q5: What were the key concerns raised by the committee regarding the evidence for blood pressure targets in individuals with type 2 diabetes, and how did these concerns impact their recommendations?\n",
      "  From chunk preview: levels, including man y wit h pre-existing car diovascular disease or r enal impairment, and \n",
      "were already r eceiving tr...\n",
      "\n"
     ]
    }
   ],
   "source": [
    "def generate_questions_for_random_chunks(chunks, num_chunks: int = 5, max_retries: int = 2):\n",
    "    selected_chunks = random.sample(chunks, num_chunks)\n",
    "    qa_pairs = []\n",
    "\n",
    "    for chunk in selected_chunks:\n",
    "        prompt = prompt = (\n",
    "            \"Based on the following text, generate an insightful question that covers its key content:\\n\\n\"\n",
    "            \"Text:\\n\" + chunk + \"\\n\\n\"\n",
    "            \"Question:\"\n",
    "        )\n",
    "\n",
    "        question = None\n",
    "        for attempt in range(max_retries):\n",
    "            try:\n",
    "                completion = openai_client.chat.completions.create(\n",
    "                    model=\"gpt-4o-mini\",\n",
    "                    messages=[{\"role\": \"user\", \"content\": prompt}]\n",
    "                )\n",
    "                question = completion.choices[0].message.content.strip()\n",
    "                if question:\n",
    "                    break\n",
    "            except Exception as e:\n",
    "                print(\"Error while generating question, retrying...\", e)\n",
    "\n",
    "        if question is None:\n",
    "            question = \"Error: could not generate question.\"\n",
    "\n",
    "        qa_pairs.append((chunk, question))\n",
    "\n",
    "    return qa_pairs\n",
    "\n",
    "questions = generate_questions_for_random_chunks(chunks_a, num_chunks=5, max_retries=2)\n",
    "for i, (chunk, q) in enumerate(questions, 1):\n",
    "    print(f\"Q{i}: {q}\\n  From chunk preview: {chunk[:120]}...\\n\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "3fd0eaf5",
   "metadata": {},
   "source": [
    "## 7. Compare two RAG configurations\n",
    "\n",
    "Now we can:\n",
    "- Use the generated questions,\n",
    "- Answer them with RAG configuration A (BGE + chunking A),\n",
    "- (Optional) Answer them with RAG configuration B (e.g. different chunking and/or different embeddings),\n",
    "- Compare the answers qualitatively.\n",
    "\n",
    "To keep the exercise manageable, we start with config A only.\n",
    "If you implemented config B, reuse `answer_query` with `index_b`, `chunks_b`, and your second embedder."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "a292474a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Question: What are the key considerations and potential impacts of the BTS/NICE/SIGN recommendations for the initial treatment and management of asthma in children and adults, particularly regarding the efficacy of combining ICS with as-needed SABA versus other strategies?\n",
      "Answer A: The key considerations and potential impacts of the BTS/NICE/SIGN recommendations for the initial treatment and management of asthma in children and adults include:\n",
      "\n",
      "1. **Efficacy of Treatment**: The recommendations highlight that using SABA (short-acting beta 2 agonist) alone has poor clinical outcomes across all age groups. Therefore, the committee emphasized that SABA should not be used as a stand-alone treatment for asthma. Instead, combination inhalers using ICS (inhaled corticosteroids) with SABA as needed are recommended to improve control of asthma symptoms.\n",
      "\n",
      "2. **Initial Treatment Strategy**: For children aged 5 to 11 years with newly diagnosed asthma, the committee recommends starting with a twice-daily low-dose ICS along with SABA as needed. This approach aims to provide better symptom management and reduce the frequency of exacerbations.\n",
      "\n",
      "3. **Management in Adolescents and Adults**: For individuals aged 12 and over, a combination of ICS with SABA is preferred for initial treatment upon diagnosis. The recommendations suggest that this combination therapy, although more expensive than SABA alone, will likely lead to cost savings in the long run due to a reduction in severe asthma exacerbations.\n",
      "\n",
      "4. **Step-Up Treatment**: If asthma is not controlled on the initial therapy, the recommendations suggest moving to higher doses or alternative combinations (e.g., low-dose ICS with LABA) before considering referral to a specialist. This structured approach is designed to ensure timely adjustments in management to maintain control.\n",
      "\n",
      "5. **Access and Cost-Effectiveness**: The recommendations also address the importance of feasibility and cost-effectiveness in implementing the proposed diagnostic pathways and treatments. The potential for reduced hospitalizations and emergency visits due to better-managed asthma is a significant factor in their economic considerations.\n",
      "\n",
      "6. **Digital Inhalers**: The committee noted the potential benefits of digital inhalers for monitoring adherence and managing treatment more effectively, suggesting a modern approach to asthma management among patients.\n",
      "\n",
      "Overall, the BTS/NICE/SIGN recommendations aim to optimize asthma management through evidence-based strategies that enhance patient outcomes and potentially reduce healthcare costs.\n",
      "Source chunk preview: (ICS) r egimens (using SABA [shor t-acting beta 2 agonist] as a r eliever) compar ed wit h 'as-\n",
      "needed' strat egies (f or example ICS/f ormot erol) as ...\n",
      "------------------------------------------------------------\n",
      "Question: What are the key components of care and guidelines that health professionals in England and Scotland should consider when diagnosing and managing patients with suspected asthma and how do these relate to principles of shared decision-making and patient experience?\n",
      "Answer A: In England, health professionals are guided by NICE guidelines that emphasize the following key components of care:\n",
      "\n",
      "1. **Shared Decision Making**: Patients should be involved in discussions and make informed decisions about their care.\n",
      "2. **Medicines Adherence**: Emphasis is placed on ensuring that patients adhere to prescribed medications.\n",
      "3. **Multimorbidity**: Consideration of patients with multiple health conditions when planning care.\n",
      "\n",
      "For diagnosing and managing asthma, the guidelines encompass:\n",
      "- Obtaining a structured clinical history that includes symptoms like wheeze, cough, breathlessness, triggers, and family history of asthma.\n",
      "- Confirming the diagnosis with supportive objective tests.\n",
      "- Engaging patients in their care discussions, aligning with the principles of shared decision-making.\n",
      "\n",
      "In Scotland, health professionals should follow similar supportive guidelines, including:\n",
      "- **Realistic Medicine**: Ensures that care is tailored to the individual and involves them in decision-making.\n",
      "- Adhering to local healthcare standards and specific asthma management guidelines.\n",
      "\n",
      "Overall, both sets of guidelines urge the incorporation of patient experience into clinical practice, promoting informed and collaborative approaches to asthma care.\n",
      "Source chunk preview: • Shar ed decision making \n",
      "• Medicines adher ence \n",
      "• Multimorbidity . \n",
      "In addition, healt h professionals in England should f ollow these NICE guideli ...\n",
      "------------------------------------------------------------\n",
      "Question: How do the changes in glucose, HbA1c, and insulin levels over 52 weeks differ between high protein (HP) and normal protein (NP) diet groups in relation to type 2 diabetes management?\n",
      "Answer A: There were no differences in changes in glucose, HbA1c, and insulin levels between the high protein (HP) and normal protein (NP) diet groups over the 52 weeks in relation to type 2 diabetes management. Both diet groups reduced glucose, HbA1c, insulin, and HOMA-IR from baseline to week 52, but the changes were similar for both groups, indicating that the diet composition (HP vs NP) did not significantly affect these parameters.\n",
      "Source chunk preview: Fat Mass, % 46.2 ± 6.2 46.6 ± 5.9\n",
      " Fat-Free Mass, % 52.9 ± 6.1 52.4 ± 5.8\n",
      "Biomarkers  (M±SD)\n",
      " HOMA-IR 7.6 ± 7.0 5.9 ± 3.4\n",
      " Glucose, mg/dL 134 ± 38 130 ...\n",
      "------------------------------------------------------------\n",
      "Question: What methodological approaches were employed in the study design to ensure accurate blood pressure measurements and statistical analysis of weight loss between the high-protein (HP) and normal-protein (NP) diet groups?\n",
      "Answer A: To ensure accurate blood pressure measurements, participants rested quietly in a seated position for at least 5 minutes with uncrossed legs and supported back and arms. Blood pressure measurements were taken two times, and if the readings differed by more than 5 mmHg, a third measurement was obtained.\n",
      "\n",
      "For statistical analysis of weight loss between the HP and NP diet groups, the study utilized various methodological approaches such as:\n",
      "\n",
      "1. A targeted sample size of 120 participants to achieve sufficient power to detect a 2.75 kg difference in weight loss based on prior study findings.\n",
      "2. Randomization performed by a statistician, stratified by age, sex, BMI, and years since diagnosis of T2D.\n",
      "3. Baseline characteristics assessed using paired t-tests or Chi-squared tests.\n",
      "4. Linear mixed models (LMM) with unstructured covariance to test the effects of diet group, time, and their interaction on changes in body weight and composition, using an intention-to-treat (ITT) approach.\n",
      "5. Comparisons of frequencies in reducing or discontinuing T2D medications assessed using Chi-squared tests.\n",
      "\n",
      "These methodologies helped ensure accurate assessments and comparisons between the two diet groups.\n",
      "Source chunk preview: Japan). Blood pressure was measured after the participant rested quietly in a seated position \n",
      "for ≥5 min with participants’ legs uncrossed and back a ...\n",
      "------------------------------------------------------------\n",
      "Question: What were the key concerns raised by the committee regarding the evidence for blood pressure targets in individuals with type 2 diabetes, and how did these concerns impact their recommendations?\n",
      "Answer A: The key concerns raised by the committee regarding the evidence for blood pressure targets in individuals with type 2 diabetes included the lack of sufficient evidence to suggest that different blood pressure targets should be recommended for these individuals, especially those with fewer additional risk factors. The committee noted that the evidence for lower blood pressure targets was limited, with some studies indicating that lowering blood pressure did not reduce the rate of cardiovascular events in this population.\n",
      "\n",
      "Additionally, the committee highlighted that previous recommendations for blood pressure targets below 130/80 mmHg in the presence of target organ damage were based on only two small studies and that there were concerns about the relevance of the study designations used in those studies. They were also aware of trial data indicating less benefit for individuals with type 2 diabetes who had fewer additional risk factors.\n",
      "\n",
      "Due to these concerns, the committee agreed that there was insufficient evidence to recommend a different blood pressure target for individuals with type 2 diabetes. Consequently, they decided to retain the clinic blood pressure target of 140/90 mmHg for adults under 80 years, applicable to people with or without type 2 diabetes, while also retaining the targets for home blood pressure monitoring (HBPM) and ambulatory blood pressure monitoring (ABPM) at 135/85 mmHg. The recommendations emphasized the importance of consistently achieving and maintaining blood pressure levels below the established targets.\n",
      "Source chunk preview: levels, including man y wit h pre-existing car diovascular disease or r enal impairment, and \n",
      "were already r eceiving tr eatment bef ore the study sta ...\n",
      "------------------------------------------------------------\n"
     ]
    }
   ],
   "source": [
    "def answer_generated_questions_a(question_tuples, k, index, chunks, embedder, client):\n",
    "    results = []\n",
    "    for chunk, question in question_tuples:\n",
    "        answer = answer_query_a(question, k, index, chunks, embedder, client)\n",
    "        results.append({\n",
    "            \"chunk\": chunk,\n",
    "            \"question\": question,\n",
    "            \"answer\": answer\n",
    "        })\n",
    "    return results\n",
    "\n",
    "results_a = answer_generated_questions_a(\n",
    "    questions,\n",
    "    k=5,\n",
    "    index=index_a,\n",
    "    chunks=chunks_a,\n",
    "    embedder=embedder_a,\n",
    "    client=openai_client,\n",
    ")\n",
    "\n",
    "for item in results_a:\n",
    "    print(\"Question:\", item[\"question\"])\n",
    "    print(\"Answer A:\", item[\"answer\"])\n",
    "    print(\"Source chunk preview:\", item[\"chunk\"][:150], \"...\")\n",
    "    print(\"-\" * 60)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "2ec212b7",
   "metadata": {},
   "source": [
    "### Extension: add RAG B and create a comparison table\n",
    "\n",
    "If you implemented a second configuration (e.g. different chunking + OpenAI embeddings):\n",
    "\n",
    "1. Build `index_b` using OpenAI embeddings and `chunks_b`.\n",
    "2. Implement `openai_embed_query`, `retrieve_texts_b`, and `answer_query_b`.\n",
    "3. Run `results_b = answer_generated_questions_b(questions, k=5, index=index_b, chunks=chunks_b, client=openai_client)`.\n",
    "4. For each question, compare:\n",
    "   - Which answer is more complete / specific?\n",
    "   - Which one is better grounded in the source chunk?\n",
    "5. Summarise your findings in a short **markdown cell** or a small table.\n",
    "\n",
    "---\n",
    "\n",
    "This concludes the core RAG exercise.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "faa74961",
   "metadata": {},
   "outputs": [],
   "source": [
    "def answer_generated_questions_b(question_tuples, k, index, chunks, client):\n",
    "    \"\"\"\n",
    "    Use RAG B to answer a list of (chunk, question) pairs.\n",
    "    \"\"\"\n",
    "    results = []\n",
    "    for chunk, question in question_tuples:\n",
    "        answer = answer_query_b(question, k, index, chunks, client)\n",
    "        results.append({\n",
    "            \"chunk\": chunk,\n",
    "            \"question\": question,\n",
    "            \"answer\": answer,\n",
    "        })\n",
    "    return results\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "e9ee1310",
   "metadata": {},
   "outputs": [],
   "source": [
    "results_b = answer_generated_questions_b(\n",
    "    questions,\n",
    "    k=5,\n",
    "    index=index_b,\n",
    "    chunks=chunks_b,\n",
    "    client=openai_client,\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "bc18c46e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question</th>\n",
       "      <th>Answer A (BGE + config A)</th>\n",
       "      <th>Answer B (OpenAI + config B)</th>\n",
       "      <th>Source chunk (A) preview</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>What are the key considerations and potential impacts of the BTS/NICE/SIGN recommendations for the initial treatment and management of asthma in children and adults, particularly regarding the efficacy of combining ICS with as-needed SABA versus other strategies?</td>\n",
       "      <td>The key considerations and potential impacts of the BTS/NICE/SIGN recommendations for the initial treatment and management of asthma in children and adults include:\\n\\n1. **Efficacy of Treatment**: The recommendations highlight that using SABA (short-acting beta 2 agonist) alone has poor clinical outcomes across all age groups. Therefore, the committee emphasized that SABA should not be used as a stand-alone treatment for asthma. Instead, combination inhalers using ICS (inhaled corticosteroids) with SABA as needed are recommended to improve control of asthma symptoms.\\n\\n2. **Initial Treatment Strategy**: For children aged 5 to 11 years with newly diagnosed asthma, the committee recommends starting with a twice-daily low-dose ICS along with SABA as needed. This approach aims to provide better symptom management and reduce the frequency of exacerbations.\\n\\n3. **Management in Adolescents and Adults**: For individuals aged 12 and over, a combination of ICS with SABA is preferred for initial treatment upon diagnosis. The recommendations suggest that this combination therapy, although more expensive than SABA alone, will likely lead to cost savings in the long run due to a reduction in severe asthma exacerbations.\\n\\n4. **Step-Up Treatment**: If asthma is not controlled on the initial therapy, the recommendations suggest moving to higher doses or alternative combinations (e.g., low-dose ICS with LABA) before considering referral to a specialist. This structured approach is designed to ensure timely adjustments in management to maintain control.\\n\\n5. **Access and Cost-Effectiveness**: The recommendations also address the importance of feasibility and cost-effectiveness in implementing the proposed diagnostic pathways and treatments. The potential for reduced hospitalizations and emergency visits due to better-managed asthma is a significant factor in their economic considerations.\\n\\n6. **Digital Inhalers**: The committee noted the potential benefits of digital inhalers for monitoring adherence and managing treatment more effectively, suggesting a modern approach to asthma management among patients.\\n\\nOverall, the BTS/NICE/SIGN recommendations aim to optimize asthma management through evidence-based strategies that enhance patient outcomes and potentially reduce healthcare costs.</td>\n",
       "      <td>The key considerations and potential impacts of the BTS/NICE/SIGN recommendations for the initial treatment and management of asthma in children and adults include:\\n\\n1. **Use of SABA Alone**: The committee found that clinical outcomes were poorest across all age groups when using short-acting beta 2 agonists (SABA) alone for asthma management. They highlighted the dangers of relying solely on SABA without inhaled corticosteroids (ICS) and recommended against its use in asthma patients.\\n\\n2. **Combination Therapy**: The evidence suggested that using a combination inhaler of ICS plus formoterol as needed (as-needed AIR therapy) notably reduced severe asthma exacerbations compared to SABA alone and also compared to regular low-dose ICS plus SABA as needed. This indicates that combining ICS with a fast-acting long-acting beta 2 agonist (LABA) is more effective.\\n\\n3. **Step-Up Treatment**: For patients whose asthma is not controlled on a combination inhaler of ICS plus formoterol used as needed, the recommendations propose specific step-up treatments, emphasizing the need for additional assessments, such as a FeNO check, before modifying treatment.\\n\\n4. **Referral to Specialists**: For individuals on high doses of ICS who still experience uncontrolled asthma, referral to a specialist in asthma care is recommended, indicating the necessity for expert management in complex cases.\\n\\n5. **Changing Treatment Protocols**: There is a clear recommendation to change treatment protocols for those using SABA only, advocating for a transition to low-dose ICS/formoterol combination inhalers as a more effective strategy.\\n\\nThese recommendations are likely to impact patient management significantly by encouraging more effective treatment strategies, reducing emergency exacerbations, and promoting better overall asthma control across all age groups.</td>\n",
       "      <td>(ICS) r egimens (using SABA [shor t-acting beta 2 agonist] as a r eliever) compar ed wit h 'as-\\nneeded' strat egies (f or example ICS/f ormot erol) as t he initial standar d treatment f or \\nasthma in ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>What are the key components of care and guidelines that health professionals in England and Scotland should consider when diagnosing and managing patients with suspected asthma and how do these relate to principles of shared decision-making and patient experience?</td>\n",
       "      <td>In England, health professionals are guided by NICE guidelines that emphasize the following key components of care:\\n\\n1. **Shared Decision Making**: Patients should be involved in discussions and make informed decisions about their care.\\n2. **Medicines Adherence**: Emphasis is placed on ensuring that patients adhere to prescribed medications.\\n3. **Multimorbidity**: Consideration of patients with multiple health conditions when planning care.\\n\\nFor diagnosing and managing asthma, the guidelines encompass:\\n- Obtaining a structured clinical history that includes symptoms like wheeze, cough, breathlessness, triggers, and family history of asthma.\\n- Confirming the diagnosis with supportive objective tests.\\n- Engaging patients in their care discussions, aligning with the principles of shared decision-making.\\n\\nIn Scotland, health professionals should follow similar supportive guidelines, including:\\n- **Realistic Medicine**: Ensures that care is tailored to the individual and involves them in decision-making.\\n- Adhering to local healthcare standards and specific asthma management guidelines.\\n\\nOverall, both sets of guidelines urge the incorporation of patient experience into clinical practice, promoting informed and collaborative approaches to asthma care.</td>\n",
       "      <td>In England, health professionals should follow the NICE guidelines which include:\\n\\n- Medicines optimisation\\n- Patient experience in adult NHS services\\n- Babies, children and young people's experience of healthcare\\n- Decision making and mental capacity\\n\\nIn Scotland, professionals should adhere to Scottish Government guidance which includes:\\n\\n- Realistic Medicine\\n- Health and social care standards\\n- Asthma: diagnosis, monitoring and chronic asthma management\\n- Mental health legislation and guidance\\n- Getting it right for every child\\n\\nWhen diagnosing and managing patients with suspected asthma, the guidelines emphasize the importance of:\\n\\n- Obtaining a structured clinical history\\n- Providing objective tests for diagnosing asthma\\n- Reviewing patients at least annually, and after exacerbations, by trained healthcare professionals\\n- Incorporating a written personalized action plan\\n- Considering telehealthcare and computerized decision support systems for self-management\\n\\nThese components are aligned with the principles of shared decision-making and patient experience by ensuring that individuals are involved in discussions and able to make informed decisions about their care. This involvement enhances their experience with the healthcare system and respects their preferences and needs.</td>\n",
       "      <td>• Shar ed decision making \\n• Medicines adher ence \\n• Multimorbidity . \\nIn addition, healt h professionals in England should f ollow these NICE guidelines f or \\npeople deliv ering car e: \\n• Medicines o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>How do the changes in glucose, HbA1c, and insulin levels over 52 weeks differ between high protein (HP) and normal protein (NP) diet groups in relation to type 2 diabetes management?</td>\n",
       "      <td>There were no differences in changes in glucose, HbA1c, and insulin levels between the high protein (HP) and normal protein (NP) diet groups over the 52 weeks in relation to type 2 diabetes management. Both diet groups reduced glucose, HbA1c, insulin, and HOMA-IR from baseline to week 52, but the changes were similar for both groups, indicating that the diet composition (HP vs NP) did not significantly affect these parameters.</td>\n",
       "      <td>The changes in glucose, HbA1c, and insulin levels over 52 weeks did not differ between the high protein (HP) and normal protein (NP) diet groups concerning type 2 diabetes management. Both diet groups significantly reduced their glucose, HbA1c, and insulin levels from baseline to week 52, but there were no differences in the changes between the HP and NP groups.</td>\n",
       "      <td>Fat Mass, % 46.2 ± 6.2 46.6 ± 5.9\\n Fat-Free Mass, % 52.9 ± 6.1 52.4 ± 5.8\\nBiomarkers  (M±SD)\\n HOMA-IR 7.6 ± 7.0 5.9 ± 3.4\\n Glucose, mg/dL 134 ± 38 130 ± 40\\n HbA1c, % 7.2 ± 1.0 7.0 ± 1.3\\n Insulin, μIU/...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>What methodological approaches were employed in the study design to ensure accurate blood pressure measurements and statistical analysis of weight loss between the high-protein (HP) and normal-protein (NP) diet groups?</td>\n",
       "      <td>To ensure accurate blood pressure measurements, participants rested quietly in a seated position for at least 5 minutes with uncrossed legs and supported back and arms. Blood pressure measurements were taken two times, and if the readings differed by more than 5 mmHg, a third measurement was obtained.\\n\\nFor statistical analysis of weight loss between the HP and NP diet groups, the study utilized various methodological approaches such as:\\n\\n1. A targeted sample size of 120 participants to achieve sufficient power to detect a 2.75 kg difference in weight loss based on prior study findings.\\n2. Randomization performed by a statistician, stratified by age, sex, BMI, and years since diagnosis of T2D.\\n3. Baseline characteristics assessed using paired t-tests or Chi-squared tests.\\n4. Linear mixed models (LMM) with unstructured covariance to test the effects of diet group, time, and their interaction on changes in body weight and composition, using an intention-to-treat (ITT) approach.\\n5. Comparisons of frequencies in reducing or discontinuing T2D medications assessed using Chi-squared tests.\\n\\nThese methodologies helped ensure accurate assessments and comparisons between the two diet groups.</td>\n",
       "      <td>The study employed the following methodological approaches to ensure accurate blood pressure measurements and statistical analysis of weight loss between the high-protein (HP) and normal-protein (NP) diet groups:\\n\\n1. **Randomization**: Participants were randomized into diet groups (HP and NP) by a statistician, which was stratified by age, sex, BMI, and years since diagnosis of type 2 diabetes (T2D). This helps control for confounding variables.\\n\\n2. **Baseline Characteristics Assessment**: Baseline characteristics were assessed by diet group, as well as the total sample, which provides a comparison point for evaluating changes.\\n\\n3. **Statistical Power Calculations**: The sample size was calculated to provide &gt;80% power to detect a specific difference in weight loss, ensuring that the study was adequately powered to detect meaningful differences.\\n\\n4. **Statistical Tests for Differences**: Differences in baseline characteristics were assessed using paired t-tests or Chi-squared tests, which are appropriate statistical methods for comparing groups.\\n\\n5. **Intention to Treat (ITT) Approach**: The analysis was conducted using an intention to treat approach, meaning that all randomized participants were included in the analysis regardless of their adherence or completion of the study.\\n\\n6. **Linear Mixed Models (LMM)**: Linear mixed models with unstructured covariance were used to test the effects of diet group, time, and their interaction term on changes in body weight and composition, ensuring that individual variability and repeated measures were accounted for.\\n\\nThese methodological approaches collectively contribute to the accuracy and reliability of the findings regarding blood pressure measurements and weight loss differences between the diet groups.</td>\n",
       "      <td>Japan). Blood pressure was measured after the participant rested quietly in a seated position \\nfor ≥5 min with participants’ legs uncrossed and back and arms supported. The measurement \\nwas taken two ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>What were the key concerns raised by the committee regarding the evidence for blood pressure targets in individuals with type 2 diabetes, and how did these concerns impact their recommendations?</td>\n",
       "      <td>The key concerns raised by the committee regarding the evidence for blood pressure targets in individuals with type 2 diabetes included the lack of sufficient evidence to suggest that different blood pressure targets should be recommended for these individuals, especially those with fewer additional risk factors. The committee noted that the evidence for lower blood pressure targets was limited, with some studies indicating that lowering blood pressure did not reduce the rate of cardiovascular events in this population.\\n\\nAdditionally, the committee highlighted that previous recommendations for blood pressure targets below 130/80 mmHg in the presence of target organ damage were based on only two small studies and that there were concerns about the relevance of the study designations used in those studies. They were also aware of trial data indicating less benefit for individuals with type 2 diabetes who had fewer additional risk factors.\\n\\nDue to these concerns, the committee agreed that there was insufficient evidence to recommend a different blood pressure target for individuals with type 2 diabetes. Consequently, they decided to retain the clinic blood pressure target of 140/90 mmHg for adults under 80 years, applicable to people with or without type 2 diabetes, while also retaining the targets for home blood pressure monitoring (HBPM) and ambulatory blood pressure monitoring (ABPM) at 135/85 mmHg. The recommendations emphasized the importance of consistently achieving and maintaining blood pressure levels below the established targets.</td>\n",
       "      <td>The key concerns raised by the committee regarding the evidence for blood pressure targets in individuals with type 2 diabetes included:\\n\\n1. **Relevance of Study Design**: The committee noted concerns about the applicability of the study population, as many participants had high cardiovascular risk levels, including pre-existing cardiovascular disease or renal impairment, and were already receiving treatment before the study started.\\n\\n2. **Insufficient Evidence**: The committee found the evidence unclear and insufficient to determine whether a lower blood pressure target would be beneficial or outweigh associated harms. They agreed that there was no evidence to suggest that blood pressure targets should be different for people with type 2 diabetes.\\n\\n3. **Limited Evidence from Studies**: Previous recommendations for individuals with type 2 diabetes suggested a blood pressure target below 130/80 mmHg; however, this was based on small studies that included participants without hypertension, and there was limited evidence indicating that lower blood pressure thresholds reduced cardiovascular events.\\n\\nThese concerns impacted their recommendations by leading the committee to retain the 2011 clinical blood pressure target of 140/90 mmHg for adults under 80 years, applicable to both those with and without type 2 diabetes. The committee also maintained that treatment thresholds should not differ for individuals with type 2 diabetes due to the lack of convincing evidence supporting a need for differing recommendations.</td>\n",
       "      <td>levels, including man y wit h pre-existing car diovascular disease or r enal impairment, and \\nwere already r eceiving tr eatment bef ore the study star ted. These concerns made t he \\nevidence difficul...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                                                                   Question  \\\n",
       "0   What are the key considerations and potential impacts of the BTS/NICE/SIGN recommendations for the initial treatment and management of asthma in children and adults, particularly regarding the efficacy of combining ICS with as-needed SABA versus other strategies?   \n",
       "1  What are the key components of care and guidelines that health professionals in England and Scotland should consider when diagnosing and managing patients with suspected asthma and how do these relate to principles of shared decision-making and patient experience?   \n",
       "2                                                                                    How do the changes in glucose, HbA1c, and insulin levels over 52 weeks differ between high protein (HP) and normal protein (NP) diet groups in relation to type 2 diabetes management?   \n",
       "3                                                What methodological approaches were employed in the study design to ensure accurate blood pressure measurements and statistical analysis of weight loss between the high-protein (HP) and normal-protein (NP) diet groups?   \n",
       "4                                                                        What were the key concerns raised by the committee regarding the evidence for blood pressure targets in individuals with type 2 diabetes, and how did these concerns impact their recommendations?   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Answer A (BGE + config A)  \\\n",
       "0  The key considerations and potential impacts of the BTS/NICE/SIGN recommendations for the initial treatment and management of asthma in children and adults include:\\n\\n1. **Efficacy of Treatment**: The recommendations highlight that using SABA (short-acting beta 2 agonist) alone has poor clinical outcomes across all age groups. Therefore, the committee emphasized that SABA should not be used as a stand-alone treatment for asthma. Instead, combination inhalers using ICS (inhaled corticosteroids) with SABA as needed are recommended to improve control of asthma symptoms.\\n\\n2. **Initial Treatment Strategy**: For children aged 5 to 11 years with newly diagnosed asthma, the committee recommends starting with a twice-daily low-dose ICS along with SABA as needed. This approach aims to provide better symptom management and reduce the frequency of exacerbations.\\n\\n3. **Management in Adolescents and Adults**: For individuals aged 12 and over, a combination of ICS with SABA is preferred for initial treatment upon diagnosis. The recommendations suggest that this combination therapy, although more expensive than SABA alone, will likely lead to cost savings in the long run due to a reduction in severe asthma exacerbations.\\n\\n4. **Step-Up Treatment**: If asthma is not controlled on the initial therapy, the recommendations suggest moving to higher doses or alternative combinations (e.g., low-dose ICS with LABA) before considering referral to a specialist. This structured approach is designed to ensure timely adjustments in management to maintain control.\\n\\n5. **Access and Cost-Effectiveness**: The recommendations also address the importance of feasibility and cost-effectiveness in implementing the proposed diagnostic pathways and treatments. The potential for reduced hospitalizations and emergency visits due to better-managed asthma is a significant factor in their economic considerations.\\n\\n6. **Digital Inhalers**: The committee noted the potential benefits of digital inhalers for monitoring adherence and managing treatment more effectively, suggesting a modern approach to asthma management among patients.\\n\\nOverall, the BTS/NICE/SIGN recommendations aim to optimize asthma management through evidence-based strategies that enhance patient outcomes and potentially reduce healthcare costs.   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               In England, health professionals are guided by NICE guidelines that emphasize the following key components of care:\\n\\n1. **Shared Decision Making**: Patients should be involved in discussions and make informed decisions about their care.\\n2. **Medicines Adherence**: Emphasis is placed on ensuring that patients adhere to prescribed medications.\\n3. **Multimorbidity**: Consideration of patients with multiple health conditions when planning care.\\n\\nFor diagnosing and managing asthma, the guidelines encompass:\\n- Obtaining a structured clinical history that includes symptoms like wheeze, cough, breathlessness, triggers, and family history of asthma.\\n- Confirming the diagnosis with supportive objective tests.\\n- Engaging patients in their care discussions, aligning with the principles of shared decision-making.\\n\\nIn Scotland, health professionals should follow similar supportive guidelines, including:\\n- **Realistic Medicine**: Ensures that care is tailored to the individual and involves them in decision-making.\\n- Adhering to local healthcare standards and specific asthma management guidelines.\\n\\nOverall, both sets of guidelines urge the incorporation of patient experience into clinical practice, promoting informed and collaborative approaches to asthma care.   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 There were no differences in changes in glucose, HbA1c, and insulin levels between the high protein (HP) and normal protein (NP) diet groups over the 52 weeks in relation to type 2 diabetes management. Both diet groups reduced glucose, HbA1c, insulin, and HOMA-IR from baseline to week 52, but the changes were similar for both groups, indicating that the diet composition (HP vs NP) did not significantly affect these parameters.   \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      To ensure accurate blood pressure measurements, participants rested quietly in a seated position for at least 5 minutes with uncrossed legs and supported back and arms. Blood pressure measurements were taken two times, and if the readings differed by more than 5 mmHg, a third measurement was obtained.\\n\\nFor statistical analysis of weight loss between the HP and NP diet groups, the study utilized various methodological approaches such as:\\n\\n1. A targeted sample size of 120 participants to achieve sufficient power to detect a 2.75 kg difference in weight loss based on prior study findings.\\n2. Randomization performed by a statistician, stratified by age, sex, BMI, and years since diagnosis of T2D.\\n3. Baseline characteristics assessed using paired t-tests or Chi-squared tests.\\n4. Linear mixed models (LMM) with unstructured covariance to test the effects of diet group, time, and their interaction on changes in body weight and composition, using an intention-to-treat (ITT) approach.\\n5. Comparisons of frequencies in reducing or discontinuing T2D medications assessed using Chi-squared tests.\\n\\nThese methodologies helped ensure accurate assessments and comparisons between the two diet groups.   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                The key concerns raised by the committee regarding the evidence for blood pressure targets in individuals with type 2 diabetes included the lack of sufficient evidence to suggest that different blood pressure targets should be recommended for these individuals, especially those with fewer additional risk factors. The committee noted that the evidence for lower blood pressure targets was limited, with some studies indicating that lowering blood pressure did not reduce the rate of cardiovascular events in this population.\\n\\nAdditionally, the committee highlighted that previous recommendations for blood pressure targets below 130/80 mmHg in the presence of target organ damage were based on only two small studies and that there were concerns about the relevance of the study designations used in those studies. They were also aware of trial data indicating less benefit for individuals with type 2 diabetes who had fewer additional risk factors.\\n\\nDue to these concerns, the committee agreed that there was insufficient evidence to recommend a different blood pressure target for individuals with type 2 diabetes. Consequently, they decided to retain the clinic blood pressure target of 140/90 mmHg for adults under 80 years, applicable to people with or without type 2 diabetes, while also retaining the targets for home blood pressure monitoring (HBPM) and ambulatory blood pressure monitoring (ABPM) at 135/85 mmHg. The recommendations emphasized the importance of consistently achieving and maintaining blood pressure levels below the established targets.   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Answer B (OpenAI + config B)  \\\n",
       "0  The key considerations and potential impacts of the BTS/NICE/SIGN recommendations for the initial treatment and management of asthma in children and adults include:\\n\\n1. **Use of SABA Alone**: The committee found that clinical outcomes were poorest across all age groups when using short-acting beta 2 agonists (SABA) alone for asthma management. They highlighted the dangers of relying solely on SABA without inhaled corticosteroids (ICS) and recommended against its use in asthma patients.\\n\\n2. **Combination Therapy**: The evidence suggested that using a combination inhaler of ICS plus formoterol as needed (as-needed AIR therapy) notably reduced severe asthma exacerbations compared to SABA alone and also compared to regular low-dose ICS plus SABA as needed. This indicates that combining ICS with a fast-acting long-acting beta 2 agonist (LABA) is more effective.\\n\\n3. **Step-Up Treatment**: For patients whose asthma is not controlled on a combination inhaler of ICS plus formoterol used as needed, the recommendations propose specific step-up treatments, emphasizing the need for additional assessments, such as a FeNO check, before modifying treatment.\\n\\n4. **Referral to Specialists**: For individuals on high doses of ICS who still experience uncontrolled asthma, referral to a specialist in asthma care is recommended, indicating the necessity for expert management in complex cases.\\n\\n5. **Changing Treatment Protocols**: There is a clear recommendation to change treatment protocols for those using SABA only, advocating for a transition to low-dose ICS/formoterol combination inhalers as a more effective strategy.\\n\\nThese recommendations are likely to impact patient management significantly by encouraging more effective treatment strategies, reducing emergency exacerbations, and promoting better overall asthma control across all age groups.   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  In England, health professionals should follow the NICE guidelines which include:\\n\\n- Medicines optimisation\\n- Patient experience in adult NHS services\\n- Babies, children and young people's experience of healthcare\\n- Decision making and mental capacity\\n\\nIn Scotland, professionals should adhere to Scottish Government guidance which includes:\\n\\n- Realistic Medicine\\n- Health and social care standards\\n- Asthma: diagnosis, monitoring and chronic asthma management\\n- Mental health legislation and guidance\\n- Getting it right for every child\\n\\nWhen diagnosing and managing patients with suspected asthma, the guidelines emphasize the importance of:\\n\\n- Obtaining a structured clinical history\\n- Providing objective tests for diagnosing asthma\\n- Reviewing patients at least annually, and after exacerbations, by trained healthcare professionals\\n- Incorporating a written personalized action plan\\n- Considering telehealthcare and computerized decision support systems for self-management\\n\\nThese components are aligned with the principles of shared decision-making and patient experience by ensuring that individuals are involved in discussions and able to make informed decisions about their care. This involvement enhances their experience with the healthcare system and respects their preferences and needs.   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 The changes in glucose, HbA1c, and insulin levels over 52 weeks did not differ between the high protein (HP) and normal protein (NP) diet groups concerning type 2 diabetes management. Both diet groups significantly reduced their glucose, HbA1c, and insulin levels from baseline to week 52, but there were no differences in the changes between the HP and NP groups.   \n",
       "3                                                                             The study employed the following methodological approaches to ensure accurate blood pressure measurements and statistical analysis of weight loss between the high-protein (HP) and normal-protein (NP) diet groups:\\n\\n1. **Randomization**: Participants were randomized into diet groups (HP and NP) by a statistician, which was stratified by age, sex, BMI, and years since diagnosis of type 2 diabetes (T2D). This helps control for confounding variables.\\n\\n2. **Baseline Characteristics Assessment**: Baseline characteristics were assessed by diet group, as well as the total sample, which provides a comparison point for evaluating changes.\\n\\n3. **Statistical Power Calculations**: The sample size was calculated to provide >80% power to detect a specific difference in weight loss, ensuring that the study was adequately powered to detect meaningful differences.\\n\\n4. **Statistical Tests for Differences**: Differences in baseline characteristics were assessed using paired t-tests or Chi-squared tests, which are appropriate statistical methods for comparing groups.\\n\\n5. **Intention to Treat (ITT) Approach**: The analysis was conducted using an intention to treat approach, meaning that all randomized participants were included in the analysis regardless of their adherence or completion of the study.\\n\\n6. **Linear Mixed Models (LMM)**: Linear mixed models with unstructured covariance were used to test the effects of diet group, time, and their interaction term on changes in body weight and composition, ensuring that individual variability and repeated measures were accounted for.\\n\\nThese methodological approaches collectively contribute to the accuracy and reliability of the findings regarding blood pressure measurements and weight loss differences between the diet groups.   \n",
       "4                                                                                                                                                                                                                                                                                                                                       The key concerns raised by the committee regarding the evidence for blood pressure targets in individuals with type 2 diabetes included:\\n\\n1. **Relevance of Study Design**: The committee noted concerns about the applicability of the study population, as many participants had high cardiovascular risk levels, including pre-existing cardiovascular disease or renal impairment, and were already receiving treatment before the study started.\\n\\n2. **Insufficient Evidence**: The committee found the evidence unclear and insufficient to determine whether a lower blood pressure target would be beneficial or outweigh associated harms. They agreed that there was no evidence to suggest that blood pressure targets should be different for people with type 2 diabetes.\\n\\n3. **Limited Evidence from Studies**: Previous recommendations for individuals with type 2 diabetes suggested a blood pressure target below 130/80 mmHg; however, this was based on small studies that included participants without hypertension, and there was limited evidence indicating that lower blood pressure thresholds reduced cardiovascular events.\\n\\nThese concerns impacted their recommendations by leading the committee to retain the 2011 clinical blood pressure target of 140/90 mmHg for adults under 80 years, applicable to both those with and without type 2 diabetes. The committee also maintained that treatment thresholds should not differ for individuals with type 2 diabetes due to the lack of convincing evidence supporting a need for differing recommendations.   \n",
       "\n",
       "                                                                                                                                                                                            Source chunk (A) preview  \n",
       "0      (ICS) r egimens (using SABA [shor t-acting beta 2 agonist] as a r eliever) compar ed wit h 'as-\\nneeded' strat egies (f or example ICS/f ormot erol) as t he initial standar d treatment f or \\nasthma in ...  \n",
       "1   • Shar ed decision making \\n• Medicines adher ence \\n• Multimorbidity . \\nIn addition, healt h professionals in England should f ollow these NICE guidelines f or \\npeople deliv ering car e: \\n• Medicines o...  \n",
       "2  Fat Mass, % 46.2 ± 6.2 46.6 ± 5.9\\n Fat-Free Mass, % 52.9 ± 6.1 52.4 ± 5.8\\nBiomarkers  (M±SD)\\n HOMA-IR 7.6 ± 7.0 5.9 ± 3.4\\n Glucose, mg/dL 134 ± 38 130 ± 40\\n HbA1c, % 7.2 ± 1.0 7.0 ± 1.3\\n Insulin, μIU/...  \n",
       "3      Japan). Blood pressure was measured after the participant rested quietly in a seated position \\nfor ≥5 min with participants’ legs uncrossed and back and arms supported. The measurement \\nwas taken two ...  \n",
       "4      levels, including man y wit h pre-existing car diovascular disease or r enal impairment, and \\nwere already r eceiving tr eatment bef ore the study star ted. These concerns made t he \\nevidence difficul...  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "rows = []\n",
    "\n",
    "for qa_a, qa_b in zip(results_a, results_b):\n",
    "    rows.append({\n",
    "        \"Question\": qa_a[\"question\"],\n",
    "        \"Answer A (BGE + config A)\": qa_a[\"answer\"],\n",
    "        \"Answer B (OpenAI + config B)\": qa_b[\"answer\"],\n",
    "        \"Source chunk (A) preview\": qa_a[\"chunk\"][:200] + \"...\"\n",
    "    })\n",
    "\n",
    "df_comparison = pd.DataFrame(rows)\n",
    "display(df_comparison)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.1"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
